PubMed Health⌕ Search

Biomedical subjects

T Chandler

Publications and source records attributed to T Chandler.

8 recordsLinked to original sources
PubMed1999

Breast cancer: outcome audit of axillary management in 1991.

AIMS: To audit the outcome of axillary treatment of patients diagnosed with invasive breast cancer in 1991, with particular reference to the incidence of regional recurrence and lymphoedema after limited axillary dissection. METHODS: A review of records of patients identified prospectively. RESULTS: Two per cent regional recurrence and 5.7% lymphoedema incidence at 5 years. CONCLUSIONS: There is no indication from these results that axillary treatment, for our patient population, should be more aggressive.

Adult↗
PubMed1997

Beef exports: looking for an opening.

BSE, food safety and the veterinarian's role in certification were among matters discussed by the BVA's President, Mr Ted Chandler, at a speech in Ballymena on October 29. Speaking at the BVA's Northern Ireland dinner, at which representatives of Government, local veterinary associations, the farming community and other organisations were present, Mr Chandler emphasised the need for the Government to recognise the veterinary profession's vital contribution to food hygiene and its pivotal role in ensuring that standards are maintained. The main text of his speech is given here.

Animals↗
PubMed1986

Effects of six-month afterload reduction therapy with hydralazine in chronic aortic regurgitation.

Seventeen patients with chronic asymptomatic aortic regurgitation (AR) were studied to determine whether 6 months of hydralazine therapy can reduce the severity of AR or reverse left ventricular (LV) enlargement and hypertrophy. Echocardiography, radionuclide angiography at rest and during exercise, and maximal treadmill exercise with respiratory gas analysis were performed at intake and after a 6-month double-blind treatment period. After dose titration with hydralazine, patients were randomized to their maximal tolerated hydralazine dose or to placebo. At intake, hydralazine and placebo groups were similar. Six patients taking hydralazine and 8 taking placebo completed the study protocol. One patient taking placebo died and 2 patients taking hydralazine withdrew with drug-related adverse effects. The mean titrated dose of hydralazine was 96 +/- 9 mg, but the mean treatment dose was 63 +/- 21 mg administered 3 times daily because of drug intolerance. After 6 months, mean systolic blood pressure with hydralazine therapy decreased from 136 to 125 mm Hg (p less than 0.02), and end-systolic posterior wall thickness increased from 1.58 to 1.70 cm (p less than 0.05), resulting in a significant reduction in M-mode meridional end-systolic stress (from 104 to 80 kdynes/cm2) (p less than 0.05). M-mode fractional shortening increased from 0.28 to 0.31 (p less than 0.05) with hydralazine, but mean LV echocardiographic dimensions were unchanged. LV mass increased from 383 to 434 g (p less than 0.05) with hydralazine primarily because of an increase in end-diastolic wall thickness. In the placebo group, there was no change in any of the hemodynamic or echocardiographic parameters at 6 months.(ABSTRACT TRUNCATED AT 250 WORDS)

Adult↗
PubMed1984

Antianginal effects of nitroglycerin patches.

Nitroglycerin (NTG) patches provide potentially therapeutic NTG blood levels for 24 hours, but their effects on exercise tolerance (ExT) in patients with angina have not been well characterized. Therefore, blinded, randomized trials were performed of the acute effects of both low-dose and maximal-tolerated-dose NTG patches and placebo on ExT in 14 patients with coronary artery disease and typical exertional angina. The bicycle exercise protocol of the National Institutes of Health was used and sublingual NTG administered as a positive control. In 7 subjects, low-dose patches produced no statistically significant effect on ExT at 4, 8 or 24 hours after administration. Comparable doses of sublingual and oral isosorbide dinitrate, NTG ointment and transmucosal NTG in previous studies have produced effects similar to those of conventional doses of sublingual NTG. Maximally tolerated doses of 2 types of NTG patches were then tested. The first (n = 8, mean NTG dose delivered 25 mg) produced increases in ExT of 82 and 72 seconds at 4 and 8 hours, respectively (both p less than 0.01), but was ineffective at 24 hours. The second patch type (n = 5, mean NTG dose delivered 22 mg) was also ineffective at 24 hours. Furthermore, even at maximal doses, peak effects on ExT were about half of those of sublingual NTG. Thus, NTG patches, even at maximal doses, appear to have smaller therapeutic effects than other long-acting nitrates and are ineffective at 24 hours. These results suggest rapid attenuation of NTG effect during prolonged maintenance of constant blood levels.

Administration, Topical↗